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SUMMARY
The pharmaceutical industry is continuously providing the
doctor with new potent drugs for his armamentarium, to
be used in the endless battle against disease. The basic
requirements for a good drug is efficacy combined with
a wide safety margin. To be able to establish this, the
new chemical substances must be tested in man. As clini-
cal investigators of new substances, we have a moral
obligation towards patients and humanity to conduct these
investigations on a sound scientific basis, taking heed not
to violate the rights and privacy of man. A personal
ethical conscience is the prime prerequisite for conducting
clinical therapeutic trials.
S. AII'. Med. J., 47, 18 (/973).
The conducting of clinical therapeutic trials is today
considered as a separate speciality of medicine, although
not universally recognized as such. Clinical therapeutic
trials, or human experimentation with drugs, are abso-
lutely necessary, because data gained from experiments
on animals cannot always be directly extrapolated onto
man as being applicable.
Variations are also found in the different animal
species. Tt is impossible to obtain data in animals regarding
drug allergy. drug idiosyncrasy and drug intolerance.
Also. the Drug Control Councils of countries. by law.
require proof that a specific drug must be tested in humans
to prove its efficacy and safety. If the human data
cannot be provided to the satisfaction of a particular
Drug Control Council. the manufacturer will not be
allowed to release the drug on the open market; con-
sequently a drug which may have been of great benefit
to humanity. will be lost. The very fact that the Drug
Control Councils require human data, is a safeguard
for patients and doctors. This requirement of human
data, gained through clinical therapeutic trials, prohibits
to a very large extent the marketing of useless and
unsafe drugs on which the public would have spent
their money. and maybe even have risked their lives.
Because of the rapid advance in the development of
pharmacology and clinical pharmacology in the past
50 years or so, the world was faced with what might
be termed :l 'chemotherapeutic revolution'. Potent Iife-
saving drugs were discovered in close succession, and
the world needed a control of some sort with regard to
this revolution. Critical analysis of data of clinical
therapeutic trials done in the past showed shortfalls
and large gaps, and these studies were rejected because
of the lack of unbiased scientific value. Some drug
trials were. and unfortunately still are. just personal
testimonials from the investigators. This unreliable :lnd
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therefore unsatisfactory practice led to the development
of a specific methodology of clinical therapeutic trials.
Soon the terminology of the methodology included
terms such as placebos, controlled studies, comparative
studies, pilot studies, single-blind studies, double-blind
studies, double-blind cross-over studies, statistical sig-
nificance, standard deviation and control groups. The
naive concept of 'poison or non-poison' is no longer
acceptable. Zbinden' compiled a classification in 1963
of clinical toxicity, listing 15 categories necessary for
clinical evaluation (Table I). The development of the
methodology therefore soon placed an additional burden
on the shoulders of the investigator or trialist in respect
of the ethical considerations, when designing a clinical
therapeutic trial.
TABLE I. DRUG-RELATED TOXIC MANIFESTATIONS IN
HUMANS' (ORDER OF CLINICAL EVALUATION)
I. Clinical pharmacology phase
1. Related to desired pharmacologic, biochemical, or
endocrine effects; exaggerated effect at recommended
dose.
2. Related to desired pharmacologic, biochemical, or en-
docrine effects; drug acting on wrong target organ.
3. Related to undesired pharmacologic, biochemical, or
endocrine effects.
4. Related to tissue irritation and damage on direct con-
tact (topical and parenteral agents only).
11. Controlled evaluation phase
1. Related to desired pharmacologic, biochemical, or
endocrine effects, requiring pre-existing pathology which
is not drug-related.
2. Related to desired pharmacologic, biochemical, or
endocrine effects, requiring contributing exogenous
factors.
3. Related to undesired pharmacologic, biochemical, or
endocrine effects, requiring pre-existing pathology which
is not drug-related.
4. Related to undesired pharmacologic, biochemical, Or
endocrine effects, requiring contributing iatrogenic and
other exogenous factors.
5. Related to interference with absorption of nutrients.
6. Related to interference with natural defence mechan-
isms.
7. Related to tissue storage or precipitation of drugs or
metabolites.
8. Toxic effects on the foetus.
Ill. Broad trial phase
1. Related to sensitization and allergic reactions.
2. Related to sensitization and allergic reactions requiring
.contributing exogenous factors.
3. Related to idiosyncrasy and other unknown mechanisms.




Claude Bernard is generally regarded as the father and
founder of experimental medicine. Dealing with the moral
and ethical aspects of human experimentation. Bernard
states in his book /tlfrod/lClion a tEfl/de de la Medecine
Experimetlfale that the principle of medical morality
consists, then, in never performing in man an experiment
which could be harmful to him in any degree whatsoever.
though the results may be of great interest to science-
that is, of benefit to save the health of others.' An
uncountable number of human experiments have been
conducted since Bernard postulated his principle of
medical ethics. Hundreds, and maybe even thousands.
of these studies were in direct conflict with the principle
laid down by Bernard. It is unfor!unately so, that the
growing extent of human experimentation led to the
abuse of the trust the patients put in the doctor. Medicine
cannot advance without investigations on human beings.
Claude Bernard accepted this and he merely asked ha,,·.
rather than why, it should be undertaken.
The most pertinent example of our time of the abuse
of the trust of the patient in the doctor, is undoubtedly
the human experimentation done by the Nazi physicians.
The methodology of the 'medical research' that was
performed, shocked the world. The 'uremberg Trial
focused the opinion of the public on medical research.
On 2 June 1948, four physicians were hanged because
they conducted clinical experimentation in a manner
which was considered to be appropriate and acceptable
to the world. After the trial which lasted 139 days. the
United States Military Tribunal umber I, rendered
a lO-point code for permissible human experimentation,
essentially summarizing the means to be employed for
protecting subjects and assuring responsible research.
A symposium on human experimentation, held 5 years
later in 1951 at the University of California. accepted
this code as a safeguard for the research worker.' and
as a standard for medico-Iegal reference:
The World Medical Association' in 1962, defined an
experiment on a human being as 'an act whereby the
investigator deliberately changes the internal or external
environment in order to observe the effects of such a
change'. Various codes of conduct for human experi-
mentation have been postulated by various bodies and
eminent individuals. Of the more recent codes the
uremberg Code (1947), the code of the Judicial Council
of the American Medical Association (1946), and the
code of the Ethical Committee of the World Medical
Association (Declaration of Helsinki, June 1964) are
the best known. The Declaration of Helsinki recognizes
a fundamental distinction in the fields of clinical research
between studies with a direct diagnostic or therapeutic
relevance to the individual patient, and research projects
carried out to advance knowledge, but from which the
subject cannot be expected to receive any direct personal
benefit.
The Judicial Code of the American Medical Association'
laid down only three requirements for human experimen-
tation, to conform to its medical ethics. They are (i)
the voluntary consent of the person on whom the
experiment is to be performed must be obtained; (ii)
the danger of each. experiment must have been previously
investigated by animal experimentation; and (iii) the
experiment must be performed under proper medical
protection and management.
Gellhorn' proposed a procedure for the decisions
based on 6 main points:
I. Work should be carried out only with the hope
of improving the patient's condition.
2. There should be a reasonable prospect of success
based on animal and other work.
3. A protocol for control work and afeguard should
be drawn up.
4. The proposed research programme should be re-
viewed by the worker's peers who are knowledgeable
in the particular field.
5. The results should be systematically collected and
analysed by independent observers.
6. The patient's written consent should be obtained
before any procedure is undertaken.
GeIlhorn believes that truly informed consent ;s
impossible. He nevertheless believes that con en! would
give the patient his rightful status as a person. and not
merely as an experimental being.
Clinical therapeutic trials can be broadly divided into
two categories, viz: early phase and later phase studies.
]n the early phase sfl/dies the main aim. and very often
the only aim, is to obtain basic scientific data on the
pharmacological effect, and if possible on the pharma-
codynamics and pharmacokinetics of the drug tested.
For the investigator doing an early phase study the
primary emphasis is therefore on basic research.
In larer phase sfl/dies the main object is to accuhlulate
data on the therapeutic value of the drug, optimum
dosage, efficacy and side-effects of a drug tested in a
large number of patients. In this type of study the in-
vestigator is primarily concerned with the patient as
a patient. The well-known aspect of the doctor-patient
relationship is therefore strongly in the foreground, as
opposed to the early phase studies. Viewed in another
way, in medical practice the patients seek the physician
(later phase studies), while in research (early phase
studies) patients are sought and selected by the physician
(investigator).
The trial population partIcIpating in controlled
therapeutic trials, can similarly be broadly c1as ified
into two categories, viz: those who stand no chance to
benefit therapeutically from the experiment, and those
who stand a very good chance to benefit therapeutically
from the study. The trial population who will not directly
benefit therapeutically from the investigation. may again
be subdivided into healthy volunteers and patient
vol unteers.
When a study is conducted using volunteers. it is of
prime importance that informed consent is obtained.
Whether the consent is written or not, is a legal rather
than a moral issue. What is of importance, however.
is that the volunteer be fully informed as to what the
study embraces. There is no right to withhold from a
prospective volunteer any fact which may influence
his decision.' Only true consent is of any value. By
true consent i meant ·con. ent freely given with proper
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understanding of the nature and consequences of what
is proposed'" Unfortunately we are not always able to
execute the above requirements to the last letter, because
a very large proportion of our population in Southern
Africa is illiterate. Interpretations and translations by
a third person to the patients are also not satisfactory,
because it is known that the majority of the patients will
fail to grasp the full meaning of the message conveyed
to them. Despite this practical problem with which we
are often confronted, we are compelled to explain to
the patient what the study entails. The investigator has
no right of persuasion, and facts should not be delibe-
rately distorted. The patient must always be informed,
that he may at any time during the investigation withdraw
from the trial. In obtaining voluntary consent, although
it may not be fully understood by the patient. the inves-
tigator realizes and acknowledges the right of the patient
as a human being. and not merely as a subject of
experimentation.
Goldstein' • suggests that the patient should be told
the following:
(i) a new drug has been developed that might be
beneficial to him;
(ii) it can only be tested properly in a controlled
way, so that some patients will receive the drug,
while others will receive a different treatment;
(iii) the assignment will be made by chance;
(iv) certain risks are likely; and
(v) other unanticipated risks may materialize.
It is impossible to construct a formal ethical code
that will embrace every circumstance that may be
encountered during clinical therapeutic trials. Patients
are still human beings and because of the complexity
and variability of the human being, as well as the ever
present individualism, it is unrealistic to subject them
to a blanket formula. Each patient and each trial
procedure should be individually judged. Should anv
question arise as to whether a certain trial or procedur~
is ethical or not, the investigator should first analyse
his own motives and then refer to the guide-lines laid
down by the various authorities. If uncertainty still
prevails, h.e must consult his peers, who should in no
way be attached to the proposed study. Final judgement
on extremely delicate situations should onlv be made
by an arbitrary panel consisting of docto;s, scientists
and responsible laymen. The emphasis of the judgement
should be placed on how the investigator intends conduct-
ing the trial, rather than on what he intends investigating.
The greatest ethical challenge to the physician
investigator. is preserving the delicate balance between
individual risk and the common good." Irrespective of
what one's religious views are, I believe that the Golden
Rule (Matthew 7 : 12), which states 'Whatsoever ye would
that men should do to you. do ye even so to them'
encapsulates everything that we understand under ethics.
It is in fact the crux of the matter because 'the cannon
of ethics of all communal living emanated from the
Golden Rule'."
CONCLUSION
Although various codes and guide-lines are available
with which the investigator can familiarize himself and
which he can use when conducting a clinical therapeutic
trial, the ultimate decisions, judgements and modus
operandi, rest in the hands of each individual investigator.
It is therefore essential that every investigator has at
least a personal code which obviously must, to some
extent, be compatible with that laid down by the various
authoritative bodies. He should therefore develop an
ethical conscience, which will not allow him to conduct
a study in such a way that he will be ashamed to have
it judged by his scientific colleagues. or by a responsible
group of laymen and scientists. It is his ethical duty to
do a trial efficiently. According to Glaser 13 'The inves-
tigator's competence is a most important prerequisite'.
Under competence is included medical skill, ethical
competence and integrity.
The integrity of an investigation is based on the
experimenter's ability to deal as honestly with conse-
quences as he tries to deal with the experimental data
and design." De Bakey states that 'obedience to an
ethical code is properly exacted by rigid, formal laws
or injunctions, but is prompted by integrity, humani-
tarianism and benevolence, qualities that every physician
should possess'."
At present, and I believe for quite some time still to
come, there is no alternative or substitute for man, in
the investigation of a new chemical substance, with the
ultimate aim of releasing this new substance on the
market. Safety and efficacy are the main prerequisites of
any drug, and to be able to establish these characteristics.
the substance must be tested in man. It is for man's
own good. The Drug Control Councils of the various
countries are continuously requiring more and more
information and data related to human experimentation
before allowing registration, for marketing purposes, of
a new substance. This is praiseworthy, but care must
be taken not to increase these requirements to such an
extent that it is no longer ethically justifiable. Doctors
are also increasing their standards of critical analvsis
of trials done with drugs. This trend is also praiseworthy,
but here again we must take heed not to be hypercritical.
If the drug-regulating bodies and the medical profession
become hypercritical in their analysis, the time will come
when legislation and laws. as opposed to our present
guide-lines, will be enforced to regulate the methodology
of clinical therapeutic trials. The execution of unscien-
tific and unethical clinical therapeutic trials must be
avoided, as far as humanly possible. Legislation and
laws are not the ideal way to accomplish this.
Abrams et aI," expressed their views as follows:
'Experience has indeed brought complexity and
sophistication, and thus, we are disturbed by the recent
trend which shifts the decision as to whether a new
drug should be used or not away from the investigators
primarily concerned, to hospital committees and gov-
ernment agencies. There should be no incompatibility
between the equally honourable objectives of delivering
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to the public important new medicines and reasonable
safety'.
The investigation of new substances in man should
?nly be entrusted to investigators who are competent.
In the broadest sense. It will be their privilege to conduct
these early phase studies. because they realize and
a~preci.a~e the heavy responsibility that accompanies
thl~ pnvtleg~. Unless an investigator has an acceptable
ethical conSCience, he should not be given the opportunity
to do clinical trials.
It is a truism that the research of todav is the routine
of tomorrow. It is therefore entirely in - our hands. as
in:esti~ators, to conduct controlled clinical therapeutic
tnals ill such a way that it does not lead to unwise
legislation in a field where reliance must be placed on
competent human judgement.
SUMMARY
A case of acute salpingitis in prp.gnancy is presented,
together with a review of the literature.
S. Air. Med. f., 47, 21 (1973).
The occurrence of acute salpingitis in pregnancy is ex-
tremely rare. and to our knowledge only a few cases have
been reported in the English literature. The rarity, to-
gether with the fact that its existence as a pathological
entity has been doubted by some authorities, have
prompted us to present our case. together with a review
of the literature.
CASE REPORT
A 32-year-old White female, gravida 6. para 4. was
admitted at 16 weeks' gestation, with lower abdominal
pain. Her previous obstetrical history showed 3 normal
vertex deliveries, followed by premature labour at 32
weeks of gestation. and a subsequent miscarriage.
She complained of colicky lower abdominal pain.
especially severe in the right iliac fossa. The pain was of
,",. D:He received: 14 August 1972.
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sudden onset and had been present for approximately 10
hours. Slight lower abdominal pains had been present
throughout the duration of the pregnancy. No history of
diarrhoea, urinary frequency or dysuria could be obtained.
The patient felt nauseous and had vomited twice.
On examination the following were found: blood pres-
sure 130/80 mmHg, pulse rate 104/minute, and normal
temperature. The abdomen showed marked tenderness with
a positive rebound sign and rigidity was found in the right
iliac fossa. Rovsing's and psoas signs were both positive.
Minimal tenderness could be elicited in the left iliac fossa.
The uterus was palpable and corre ponded in size to a 16-
week gestation period. No signs of intestinal ileu. free
fluid or abdominal distension were found.
Vaginal examination confirmed the size of the uterus.
and showed marked tenderness on the right.
Special investigations that were done included: erythro-
cyte sedimentation rate 120 mm/hour (Westergren). white
cell count 23 I SO/mm'; haemoglobin 11.0 gjlOO ml; blood
group B Rh +: urinalysis-normal.
MANAGEMENT
A provisional diagnosis of acute appendicitis in pregnancy
was made. and it was decided to proceed with an appendi-
cectomy.
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